[Clinical characteristics and therapeutic effect of drug-resistant tuberculosis in children]

Q Liao1, S Tan, Y Zhu

  • 1Department of Pediatrics, West China Second Hospital, Sichuan University Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu 610041, China.

Insights

This study found that second-line anti-tuberculosis (TB) therapy is effective for drug-resistant TB in children, with a low incidence of adverse drug reactions. The research analyzed clinical characteristics and treatment outcomes in pediatric patients.

Area of Science:

  • Pediatric infectious diseases
  • Clinical microbiology
  • Public health

Background:

  • Drug-resistant tuberculosis (TB) poses a significant challenge in pediatric populations.
  • Understanding the clinical profile and treatment outcomes of drug-resistant TB in children is crucial for effective management.
  • Second-line anti-TB therapies are essential for treating resistant strains but require careful evaluation for efficacy and safety in children.

Purpose of the Study:

  • To investigate the clinical characteristics of drug-resistant TB in children.
  • To evaluate the effectiveness of second-line anti-TB therapy in pediatric patients.
  • To determine the incidence of adverse drug reactions associated with these treatments.

Main Methods:

  • Retrospective analysis of clinical records of children diagnosed with drug-resistant TB.
  • Data collected from West China Second Hospital between January 2010 and June 2014.
  • Statistical analysis, including chi-squared test, to examine clinical characteristics, risk factors, treatment effectiveness, and adverse drug reactions.

Main Results:

  • A drug resistance rate of 10.4% was observed in 46 pediatric TB patients.
  • The majority of patients were in the >7 to 14 years age group (54.3%).
  • An overall effective treatment rate of 87.0% was achieved, with an adverse drug reaction incidence of 10.9%.

Conclusions:

  • Second-line anti-TB therapy demonstrates significant effectiveness in treating drug-resistant TB in children.
  • The incidence of adverse drug reactions associated with these therapies in pediatric patients is relatively low.
  • Clinical characteristics and risk factors, such as close contact with TB patients and prior irregular treatment, are important considerations.

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
719
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
343
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
583
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
304
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
405